| 注册
首页|期刊导航|中国临床药理学杂志|曲美他嗪片治疗冠心病伴心力衰竭合并心房颤动的临床研究

曲美他嗪片治疗冠心病伴心力衰竭合并心房颤动的临床研究

刘立志 张丹 王菊飞 姜成 陆曹杰 陈加才 邬武斌 毛海慧 崔晶星

中国临床药理学杂志2018,Vol.34Issue(3):218-220,3.
中国临床药理学杂志2018,Vol.34Issue(3):218-220,3.DOI:10.13699/j.cnki.1001-6821.2018.03.008

曲美他嗪片治疗冠心病伴心力衰竭合并心房颤动的临床研究

Clinical trial of trimetazidine tablets in the treatment of coronary heart disease with heart failure and atrial fibrillation

刘立志 1张丹 1王菊飞 1姜成 1陆曹杰 1陈加才 1邬武斌 1毛海慧 1崔晶星1

作者信息

  • 1. 奉化市人民医院心内科,浙江 奉化 315500
  • 折叠

摘要

Abstract

Objective To observe the clinical efficacy and safety of trimetazidine tablets in the treatment of coronary heart disease with heart failure and atrial fibrillation.Methods A total of 226 patients of coronary heart disease with heart failure and atrial fibrillation were randomly divided into control and treatment groups with 113 cases per group.Control group was treated with aspirin,clopidogrel,statins,angiotensin converting enzyme inhibitor and other conventional therapy.Treatment group was given trimetazidine 20 mg per time,tid,orally,on the basis of control group.Two groups were treated for 6 months.The clinical efficacy,6 min walk test,metabolic syndrome (Mets) score,lipoprotein associated phospholipase A2 (Lp-PLA2),NT-brain natriuretic peptide (NT-proBNP),tumor necrosis factor-α (TNF-α) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 84.07% (95 cases/ll3 cases) and 65.49% (74 cases/ll3 cases) with significant difference (P < 0.05).After treatment,the main indexes in treatment and control groups were compared:the distance of 6 min walking test were (378.45 ± 82.31) and (352.14 ± 63.23) m,Mets score were (2.14 ± 0.50) and (1.82 ± 0.28) points,Lp-PLA2 were (397.24 ± 135.98) and (481.20 ± 139.15) U · L-1,NT-proBNP were (2084.35 ±1074.47) and (4611.25 ±1299.74) pg· mL-1,TNF-α were (12.94 ±6.03) and (23.10±6.78) ng · mL-1,the differences were statistically significant (all P < 0.05).There were no adverse drug reactions in two groups during the treatment.Conclusion Trimetazidine tablets have a definitive clinical efficacy and safety in the treatment of coronary heart disease with heart failure and atrial fibrillation.

关键词

曲美他嗪片/冠心病/心力衰竭/心房颤动/安全性

Key words

trimetazidine tablet/coronary heart disease/heart failure/atrial fibrillation/safety

分类

天文与地球科学

引用本文复制引用

刘立志,张丹,王菊飞,姜成,陆曹杰,陈加才,邬武斌,毛海慧,崔晶星..曲美他嗪片治疗冠心病伴心力衰竭合并心房颤动的临床研究[J].中国临床药理学杂志,2018,34(3):218-220,3.

基金项目

奉化市第八批科技基金资助项目(201508809) (201508809)

中国临床药理学杂志

OA北大核心CSCDCSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文